Tag: Pembrolizumab

Keytruda® (generic: pembrolizumab) is a humanized monoclonal antibody that works as an immune checkpoint inhibitor, targeting PD-1 (programmed death-1) to restore anti-tumor immune responses. First approved by the FDA in 2014, it has since become a cornerstone in modern oncology across a wide array of solid and hematologic malignancies. 🧬 Mechanism of Action Pembrolizumab blocks…